Oncology testing services company NeoGenomics Inc (NASDAQ: NEO) announced on Wednesday that it will present three key studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona from 13-17 September. The studies emphasise the value of circulating tumour DNA (ctDNA) analysis and next-generation sequencing (NGS) in advancing early cancer detection and personalised treatment.
Among the highlights, data from a real-world analysis show NGS testing for multiple gene fusions can identify four times more patients eligible for matched therapies than traditional methods. Another study on ctDNA in early-stage non-small cell lung cancer (NSCLC) pinpoints patients at high relapse risk, guiding more aggressive treatment strategies. A third trial explores ctDNA as a marker to inform treatment in high-risk melanoma, comparing combined anti-LAG-3 and anti-PD-1 therapies with anti-PD-1 alone.
NeoGenomics, headquartered in Fort Myers, FL, is a leader in cancer genetics testing, offering comprehensive services for healthcare providers and pharmaceutical clients across multiple certified laboratories in the US and UK.
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment